Abstract  Description  Claims  Drawing  Search report  Cited references 

WO2012160006A   [0011] 

Remington's Pharmaceutical Sciences   [0056] 
Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors   [0200] 
Activation of the sympathetic nervous system mediates hypophagic and anxiety-like effects of CB□ receptor blockade   [0200] 
Remington: the science and practice of pharmacy   [0200] 
Outcome Measures for Clinical Trials in Fragile X Syndrome   [0200] 
Depression-like phenotype following chronic CB1 receptor antagonism   [0200] 
Traitement pharmacologique de la maladie d'Alzheimer et des maladies apparentées: rapport d'évaluation des technologies de la santé   [0200] 
The Quality of Life Scale (QOLS): reliability, validity, and utilization   [0200] 
Targeting the endocannabinoid system in the treatment of fragile X syndrome   [0200] 
Efficacy of rimonabant and other cannabinoid CB1 receptor antagonists in reducing food intake and body weight: preclinical and clinical data   [0200] 
Meeting at the crossroads: common mechanisms in Fragile X and Down syndrome   [0200] 
Human and mouse model cognitive phenotypes in Down syndrome: implications for assessment   [0200] 
One-trial object recognition in rats and mice: methodological and theoretical issues   [0200] 
Outcome Measures for Clinical Trials in Down Syndrome   [0200] 
Evidence for a virtual human analog of a rodent relational memory task: A study of aging and fMRI in young adults   [0200] 
Pharmacological approaches to improving cognitive function in Down syndrome: current status and considerations   [0200] 
Down syndrome: Cognitive and behavioral functioning across the lifespan   [0200] 
Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial   [0200] 
The NIH Toolbox Cognitive Battery for intellectual disabilities: three preliminary studies and future directions   [0200] 
Epidemiology of fragile X syndrome: a systematic review and meta-analysis   [0200] 
Modeling fragile X syndrome in the Fmr1 knockout mouse   [0200] 
Donepezil for treatment of cognitive dysfunction in children with Down syndrome aged 10-17   [0200] 
Employment in Adults with Down Syndrome in the United States: Results from a National Survey   [0200] 
Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons   [0200] 
Studying the impact of aging on memory systems: contribution of two behavioral models in the mouse   [0200] 
Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression   [0200] 
Modeling depression in animal models   [0200] 
Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling   [0200] 
Characterization of two cloned human CB1 cannabinoid receptor isoforms   [0200] 
AM-251 and rimonabant act as direct antagonists at muopioid receptors: Implications for opioid/cannabinoid interaction studies   [0200] 
Temporal binding function of dorsal CA1 is critical for declarative memory formation   [0200] 
Assessment scales in dementia   [0200] 
Allosteric Modulation of a Cannabinoid G Protein-coupled Receptor: BINDING SITE ELUCIDATION AND RELATIONSHIP TO G PROTEIN SIGNALING   [0200] 
Pregnenolone can protect the brain from cannabis intoxication   [0200] 
PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations   [0200] 
The use of the elevated plus maze as an assay of anxiety-related behavior in rodents   [0200] 
Effects of the cannabinoid antagonist SR 141716 on sexual and motor behaviour in receptive female rats   [0200] 
Diagnostic and statistical manual of mental disorders: DSM-5   [0200] 
Rapport d'évaluation des médicaments indiqués dans le traitement symptomatique de la maladie d'ALZHEIMER   [0200] 
Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease   [0200] 
EPAR discussion   [0200]